SMFM statement on NIH treatment guidelines

SMFM supports the new NIH COVID-19 Treatment guidelines.

The following pertains to treatment for pregnant patients:

• Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets): no pregnancy data on nirmetrelvir, limited supply, consider drug-drug interactions
• Sotrovimab: limited supply that is mostly reserved for highest risk immunocompromised and elderly
• Remdesivir (3 day outpatient regimen): extensive pregnancy experience but requires multiple infusions

All of the above have similar efficacy at preventing hospitalization and death; despite no pregnancy-specific data

• Molnupiravir: 30% efficacy; EUA recommends against use in pregnancy but may reasonably consider use in pregnancy if no other therapies available and with documented counseling